NY-WELLA-COMPANY
1.12.2022 15:13:38 CET | Business Wire | Press release
Wella Company, a global leader in the $100 billion hair and nail segment of the beauty industry, is marking a successful second year as a standalone company, delivering year-over-year double-digit profit and growth ahead of expectations. In Fiscal Year 22, which closed at the end of June, Wella Company beat all targets on financial performance across the globe. Since its founding in December 2020, Wella Company has delivered continuous double-digit profit and growth ahead of expectations and is one of the fastest-growing beauty companies in the sector.
Wella Company’s portfolio includes iconic professional and retail hair, nail, and beauty tech brands Wella Professionals, O·P·I, ghd, Briogeo, Nioxin, Sebastian Professional, and Clairol.
“Our first two years of business have shown the enduring potential of the Wella Company portfolio – we are re-establishing category excellence in both hair and nails, and both professionals and consumers are falling in love again with our beautiful brands,” said Annie Young-Scrivner, CEO of Wella Company. “Our continued strong financial performance, coupled with growth and gain in market share across all categories, even in the challenging global context, is proof that our business is just beginning to tap into its full potential.”
Product Portfolio Expansion and Successes
Wella Professionals continues to lead the company’s overall portfolio growth, with double-digit performance, retaining its #1 share in Professional Color globally. The launch of Shinefinity, a professional glazing service and a new category entry for Wella Company, was the company’s strongest color launch ever, delivering +4% above target. Momentum is building behind the Care portfolio, led by Wella Care, Sebastian and Nioxin, all generating double-digit growth. Sebastian Professional is Wella Company’s second-largest pro brand and achieved double-digit growth this year with gains across all key markets, driven by the brand’s unique care/styling hybrid products such as Dark Oil and No Breaker. Nioxin continued to deliver strong performance with Net Revenue growing double-digit year-on-year in key regions like NA and EMEA. The company’s Retail Hair segment grew Net Revenue nearly +3% in FY22 while gaining share across most key markets.
The Briogeo acquisition (closed June 2022) further solidified the company’s eco-ethical haircare portfolio by adding the clean and green, natural hair care business, one of the fastest-growing brands today. Briogeo sells one of its award-winning Don't Despair, Repair! Deep Conditioning Masks every minute.
London-based ghd (good hair day) is redefining beauty tech and continues to dominate with its digital-centric strategy. The brand has delivered on average a double-digit annual growth rate over the last 4 years.
O·P·I is the #1 professional nail brand worldwide and #3 in US retail. In the US, the brand has seen 10 months of consecutive share gain in the Food, Drug, Mass (FDM) channel. Nature Strong, the brand’s first plant-based, natural origin nail lacquer, was the #1 Color Cosmetics Launch in all FDM this spring.
Expansion in eCommerce and Digital
Wella Company continues to propel growth by expanding its digital footprint and accelerating eCommerce. Its WellaStore B2B eCommerce platform continues to acquire customers globally, helping salon pros meet business needs from express ordering to planning their bookings to accessing training. In FY22, WellaStore grew its sales volume +30% and grew its customer base by +10%. In its consumer eCommerce channels, the company grew nearly 2.5x faster than the overall hair market, especially in EMEA and APAC.
Commitment to ESG
As the company continues to grow, it is furthering its commitment to sustainability and social impact via its three pillars: People, Planet and Products. In June 2022, Wella Company announced its environmental targets and its participation in the UN Global Compact, the world’s largest initiative for sustainability in business. In tandem with its second anniversary, Wella Company issued its ESG Manifesto, the first formal publication of its commitment to environmental, social and governance (ESG), as well as a new Code of Conduct, WE Care. The Company will issue its first formal ESG report in 2023.
About Wella Company
Wella Company is an innovative global leader in the beauty industry that combines 140+ years of earned wisdom and industry experience with the momentum of a newly minted independent entity. Now marking two years as a standalone company, Wella Company is one of the fastest-growing beauty companies in the sector. The company has a portfolio of iconic professional and retail hair, nail, and beauty tech brands including Wella Professionals, O·P·I, ghd, Briogeo, Nioxin, Sebastian Professional, and Clairol. The company serves legions of artists and owners across the professional hair and nail community in more than 100 countries. Each day, a diverse community of more than 91 million beauty lovers and industry professionals, social influencers, ambassadors, followers, employees, and customers engage with and are impacted by Wella Company products across the globe. With the belief that business can be a catalyst for positive change, Wella Company acts to enable people, organizations, and societies to collectively prosper. Environmental, Social, and Governance (ESG) is at the core of Wella Company’s purpose-led agenda. Sustainability and Diversity, Equity and Inclusion are fundamental to who we are, how we operate and how we support the industry and communities we serve. Wella Company is building the best beauty company in the industry, ensuring that when the industry thrives, we thrive. And as we make progress on our agenda to care for our planet and leave a positive impact on society, we will become a champion for change whose legacy will be worthy of our iconic history. For more information on Wella Company, visit www.wellacompany.com and follow us on LinkedIn and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005715/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom